Skip to main content

Grafa News and Videos — Page 1634

Latest

Grafa

BioLineRx initiates Phase 1/2a trial of GLIX1 for glioblastoma following 2025 financial results

BioLineRx (NASDAQ:BLRX), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the initiation of a first-in-human Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.

Read more: BioLineRx initiates Phase 1/2a trial of GLIX1 for glioblastoma following 2025 financial results

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift